(Sharecast News) - Syncona announced the launch of Slingshot Therapeutics, a new portfolio company and accelerator dedicated to developing early-stage life science programs sourced from academia, on Thursday.
The FTSE 250 company said it had committed an initial £12.5m to Slingshot, with a current holding value of £5.6m following the first...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE